NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Estimated value
—
Awarded value
—
Suppliers
14
Lots
7
Published
19 Jul 2022
Description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. <br/>Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Scope
- Reference
- CM/PHS/19/5583
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Security of Supply | 20% | quality | — |
| Ease of Use | 10% | quality | — |
| — | 70% | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 14 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 7 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 – C1 Esterase – Recombinant IV (acute treatment) | — | cancelled |
| 3 | Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment) | — | cancelled |
| 6 | Lot 6 - Lanadelumab | — | cancelled |
| 7 | Lot 7 - Berotralstat | — | cancelled |
| 2 | Lot 2 - C1 Esterase – Plasma derived IV (acute treatment) | — | cancelled |
Award 1· 1 supplier
Awarded —
Award 2· 1 supplier
Awarded —
Award 3· 1 supplier
Awarded —
Award 4· 1 supplier
Awarded —
Award 5· 1 supplier
Awarded —
Award 6· 1 supplier
Awarded —
Award 7· 1 supplier
Awarded —
Award 8· 1 supplier
Awarded —
Award 9· 1 supplier
Awarded —
Award 10· 1 supplier
Awarded —
Award 11· 1 supplier
Awarded —
Award 12· 1 supplier
Awarded —
Award 13· 1 supplier
Awarded —
Award 14· 1 supplier
Awarded —
Total lots
7
Awarded
5
Estimated total
—
Awarded total
—
Lot 1 – C1 Esterase – Recombinant IV (acute treatment)
Start
—
End
—
Estimated
—
CPV
Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment)
Start
—
End
—
Estimated
—
CPV
Lot 6 - Lanadelumab
Start
—
End
—
Estimated
—
CPV
Lot 7 - Berotralstat
Start
—
End
—
Estimated
—
CPV
Lot 2 - C1 Esterase – Plasma derived IV (acute treatment)
Start
—
End
—
Estimated
—
CPV
Lot 4 - C1 Esterase – Plasma derived Subcut (prophylaxis treatment)
Start
—
End
—
Estimated
—
CPV
Lot 5 - Icatibant
Start
—
End
—
Estimated
—
CPV
Other contracts from NHS England
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Pharming Group· 4
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NP48925c Hereditary Angioedema Branded Medicines (Ruconest) | contract | — | 02 May 2025 |
| NHS Framework Agreement for Branded Medicines - Proprietary Category Tender - 1 May 2025 | contract | — | 22 Apr 2025 |
| NP48925c Hereditary Angioedema Branded Medicines (Ruconest) | contract | — | 04 Apr 2025 |
| Human Derived Blood Products | contract | — | 28 Aug 2024 |